Eli Lilly`s nationwide insulin pricing settlement called off
EU regulator signs off on Novo's weekly insulin and other meds
SAN DIEGO, June 24, 2023 /PRNewswire/ -- Novo Nordisk today announced that data from the phase 3a ONWARDS 1 and 3 trials evaluating investigative once-weekly insulin icodec, which were presented at the 83rd Annual Scientific Sessions of the American Diabetes Association (ADA), showed the studies met their primary endpoints and insulin icodec provided similar glucose-lowering effects (change in HbA1C from baseline) while reducing injections from seven to one per week compared with once-daily basal insulin1-2. Additionally, data from the ONWARDS 1 and 3 studies demonstrated that more insulin-naïve adults with type 2 diabetes treated with insulin icodec achieved an HbA1c target of <7.0% without experiencing clinically significant or severe hypoglycemia compared with once-daily basal insulin comparators at 52 and 26 weeks, respectively1-2.
Tecan to present at upcoming Investor Conferences
As a recent PhRMA analysis shows, the cost of filling a prescription can add up, and lead to nonadherence or worse. For patients filling a brand-name prescription drug in the deductible (before the insurance kicks in), patients paid eight times more, on average, for their medicine than a patient filling a brand prescription with a copay.
Ahead of World Diabetes Day today, WHO hosted several private sector entities who have expressed new commitments and proposed contributions to requested WHO Asks or strengthened previous commitments to increase access to insulin and health technologies.
A device known as a bionic pancreas, which uses next-generation technology to automatically deliver insulin, was more effective at maintaining blood glucose (sugar) levels within normal range than standard-of-care management among people with type 1 diabetes, a new multicenter clinical trial has found. The trial was primarily funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health (NIH), and published in the New England Journal of Medicine.
An insulin-suppressing protein may be responsible for the five-fold increase in longevity in queen ants compared to worker ants, noted a recent study.
When the FDA originally cleared the automated, tubeless system in January of this year, Omnipod 5 was made available for use by people with Type 1 diabetes who were at least 6 years old. A new nod from the agency, however, brings the technology to the preschool level: It’s now available to Type 1 patients as young as 2, Insulet announced Monday.
It’s just days before the Senate is supposed to leave town for summer break, and they’re still engaged in a last-minute scramble to streamline their ambitious plan to lower drug prices. My colleague Rachel Cohrs has the details on what’s already changed — and what’s still changing.